Compare Amgen, Inc. (AMGN) vs Waste Management, Inc. (WM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Waste Management, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Waste Management, Inc. trades at $234.4 (market cap $93.70B). The key difference: Amgen, Inc. is far larger — about 2.1× Waste Management, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WM | |
|---|---|---|
Market Cap | $196.12B | $93.70B |
Sector | Health | Industrials |
52-Week High | $388.16 | $246.51 |
52-Week Low | $271.18 | $196.77 |
Enterprise Value | $241.41B | $116.43B |
Dividend Yield | 2.77% | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
WM trades at $233.33, up 0.72% today, showing steady performance near its 52-week high. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters show mixed earnings results. Analyst consensus remains positive with a $263.57 price target. The company continues its dividend payments, with the next $0.95 dividend scheduled for June 2026.
Outlook: WM's defensive business model and pricing power provide stability, but elevated valuation ratios (P/E 33.77) pose risks if growth slows. Upside potential exists if the company meets Q2 2026 earnings expectations. Key risks include debt levels and economic sensitivity. Wall Street's strong buy sentiment (57% buy ratings) supports a cautiously optimistic view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
